




- (51) **International Patent Classification:**
C07D 233/46 (2006.01)
- (21) **International Application Number:**
PCT/IB2013/055099
- (22) **International Filing Date:**
21 June 2013 (21.06.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1255917 22 June 2012 (22.06.2012) FR
- (71) **Applicant:** SANOFI [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).
- (72) **Inventors:** EL-AHMAD, Youssef; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). FILOCHE-ROMME, Bruno; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). LETALLEC, Jean-Philippe; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). MARCINIAK, Gilbert; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). RONAN, Baptiste; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). VIVET, Bertrand; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).
- (74) **Agent:** BOURGOUIN-MULLER, Alessandra; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
— of inventorship (Rule 4.17(iv))

[Continued on next page]

(54) **Title:** NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this 1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF



(I)

formula 1a



formula 1b



(57) **Abstract:** The invention relates to the novel products of formula (I) with p, q = 0, 1 or 2; R1 = phenyl, pyridyl; $-(CH_2)_m$ -Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; $-SO_2$ -Rb; $-CO$ -Re; m = 1 or 2; Ra = aryl, heteroaryl, $-CO$ -cycloalkyl, $-CO$ -heterocycloalkyl, $-CO$ -Rb, $-C(Rb)=N-ORc$, $-CO$ 2 Rd, $-CONR_xR_y$; Rb = alkyl, aryl, heteroaryl; Rc = H, alkyl; Rd = alkyl, cycloalkyl; Re = alkyl, cycloalkyl, aryl, heteroaryl; NR_xR_y with Rx, Ry = H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3 = H, alkyl, CF₃, or form with C a ring with optionally O, S and N; R4 = H, F, Cl, CH₃ or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is (Formula 1a) and the isomer of configuration R,R (Formula 1b) these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.



Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*